Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2Small Cell Lung Carcinoma 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Ovarian Neoplasms 1MET Positive 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 49Fluorouracil 45Leucovorin 42Capecitabine 40Irinotecan 31Bevacizumab 31Radiotherapy 24Cetuximab 23Radiation 13Panitumumab 13Folfox protocol 10Surgical Procedures, Operative 9IFL protocol 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6aflibercept 5Immunohistochemistry 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Fluorodeoxyglucose F18 4Floxuridine 4Celecoxib 4trifluridine tipiracil drug combination 3dehydroftorafur 3XELOX 3Sorafenib 3Ramucirumab 3Neoadjuvant Therapy 3Erlotinib Hydrochloride 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rectal Neoplasms × rilotumumab × Clear all
NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡